Compare · ANTX vs NVO
ANTX vs NVO
Side-by-side comparison of AN2 Therapeutics Inc. (ANTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 1278.3x ANTX ($135.9M).
- Both names hit the wire about 4 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 13 for ANTX).
- Company
- AN2 Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $3.38-5.98%
- $38.82-1.05%
- Market cap
- $135.9M
- $173.66B
- 1M return
- -
- -10.14%
- 1Y return
- -
- -30.77%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 4
- 4
- Recent ratings
- 13
- 25
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANTX
- SEC Form 4 filed by AN2 Therapeutics Inc.
- SEC Form 4 filed by AN2 Therapeutics Inc.
- SEC Form 4 filed by AN2 Therapeutics Inc.
- AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
- Chief Medical Officer Trenor Cameron C. Iii was granted 116,667 shares (SEC Form 4)
- AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
- SEC Form S-8 filed by AN2 Therapeutics Inc.
- Director Readnour Robin Shane sold $6,675 worth of shares (1,108 units at $6.02) as part of a pre-agreed trading plan (SEC Form 4)
- Director Readnour Robin Shane sold $97,323 worth of shares (16,119 units at $6.04) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fitzpatrick Margaret M bought $11,602 worth of shares (2,098 units at $5.53), increasing direct ownership by 24% to 10,708 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank